Overview


According to FutureWise analysis the market for Hypoparathyroidism Treatment in 2023 is US$ 1.09 billion, and is expected to reach US$ 2.2 billion by 2031 at a CAGR of 8.5%.

Hypoparathyroidism is an endocrine disorder in which the parathyroid glands, which are found in the neck region and do not produce enough parathyroid hormone (PTH). The optimal level of calcium, phosphate, and calcitriol (active Vitamin D) in the blood and bones is crucially maintained by the parathyroid hormone (PTH). A rare endocrine condition called hypoparathyroidism is brought on by inadequate or non-existent parathyroid hormone production. Supplementing the body with vitamins and minerals to balance the levels of calcium and phosphorus in the blood is one of the most prevalent treatments for hypoparathyroidism which includes taking calcium carbonate pills or high doses of vitamin D orally.

When there is not enough PTH, calcium levels drop and phosphorus levels increase, leading to symptoms such as muscle cramps, twitching, and spasms, as well as numbness and tingling in the fingers, toes, and around the mouth. There are several causes of hypoparathyroidism, including genetic mutations, autoimmune disorders, surgery, radiation therapy, or damage to the parathyroid glands due to injury or infection. While there is no permanent cure for hypoparathyroidism, the development of innovative and more effective treatments is likely to improve the lives of those who suffer from this condition. As research continues in this field, we can expect to see new innovations and breakthroughs that will help to improve the diagnosis and treatment of hypoparathyroidism.

FutureWise Market Research has published a report that provides an insightful analysis of Hypoparathyroidism Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Hypoparathyroidism Treatment Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Shire-NPS Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • EnteraBio Ltd.
  • WCCT Global Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Hypoparathyroidism Treatment Market:

The successful completion of the second stage study for BridgeBio Pharma's experimental drug encaleret was announced in March 2021. In patients with autosomal dominant hypocalcaemia type 1, the medicine has shown to be quite effective in treating hypoparathyroidism.

The primary factor anticipated to propel market expansion is the rising prevalence of thyroid, head, and neck cancers. The global market for hypoparathyroidism treatments is expected to gain speed and present potential prospects as a result of rising investments in research and development and the creation of biologics.

Based on the method of administration, the oral segment dominates the market for treating hypoparathyroidism. The blood calcium level can be increased by taking oral calcium supplements. However, calcium supplements can have adverse effects on the gastrointestinal tract, including constipation, when used in large dosages, government imposed stringent regulations and longer time duration required for the approval of hypoparathyroidism drug can hamper the market growth to a certain extent.

The market for hypoparathyroidism treatments is dominated by the vitamin D analogue. To be therapeutically effective, a vitamin D analogue needs to bind properly to the VDR. The 1a-hydroxyl group-containing A-ring is the primary structural component of the vitamin D molecule required for VDR binding. The human body can absorb calcium and remove phosphorus with the aid of high amounts of vitamin D, typically in the form of calcitriol.

By Drug Class

  • Parathyroid Hormone
    • Natpara
    • Others
  • Vitamin D Analogue
    • Vitamin D2
    • Vitamin D3
  • Calcium Supplements

By Route of Administration

  • Oral
  • Parental

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The hypoparathyroidism treatment market is expected to be driven by the North America region due to the increasing prevalence of hypoparathyroidism in the region, the expansion of pharmaceutical companies' efforts to develop innovative formulations, as well as the availability of advanced healthcare infrastructure and skilled healthcare professionals. The market in this region is expanding due to an increase in thoracic procedures and cancer incidence. Additionally, on a global scale, based on route of administration; oral and parenteral hold a market share of 51.9% and 48.1% respectively in 2022.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Hypoparathyroidism Treatment Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Hypoparathyroidism Treatment Market Variables, Trends and Scope
    •   1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Hypoparathyroidism Treatment Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Hypoparathyroidism Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Hypoparathyroidism Treatment Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Parathyroid Hormone
         1.1. Natpara
         1.2. Others
        2. Vitamin D Analogue
         2.1. Vitamin D2
         2.2. Vitamin D3
        3. Calcium Supplements

  • 8.   Hypoparathyroidism Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parental

  • 9.   Hypoparathyroidism Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Sales

  • 10.   North America Hypoparathyroidism Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Hypoparathyroidism Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Hypoparathyroidism Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Hypoparathyroidism Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Shire-NPS Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. F. Hoffmann-La Roche Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sun Pharmaceutical Industries Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AbbVie Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. EnteraBio Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. WCCT Global Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Novartis AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Takeda Pharmaceutical Company Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients